Immutep to Participate in The JMP Securities Hematology and Oncology Summit
Immutep Limited (ASX: IMM; NASDAQ: IMMP) has announced that CEO Marc Voigt will present at The JMP Securities Hematology and Oncology Summit on December 7, 2022, at 11:20 am EST. The event is virtual, offering one-on-one meetings with Mr. Voigt. A live webcast of the presentation will be accessible via their website and archived for later viewing. Immutep focuses on developing LAG-3 immunotherapies for cancer and autoimmune diseases, with lead candidate eftilagimod alpha being tested in various clinical trials.
- None.
- None.
Media Release
SYDNEY, AUSTRALIA, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announced that Marc Voigt, CEO, will participate in The JMP Securities Hematology and Oncology Summit, a virtual investor event to be held from December 6-7, 2022.
Presentation Details:
Date: Wednesday, 7 December 2022
Time: 11:20am EST
Mr. Voigt will be available for virtual one-on-one meetings during the conference. A live webcast of his presentation will be available here and after the meeting under the Events page within the Investors & Media section of Immutep’s website.
About Immutep
Immutep is a clinical stage biotechnology company leading the development of LAG-3 related immunotherapy products for the treatment of cancer and autoimmune disease. The Company is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximise value to shareholders.
Immutep’s lead product candidate is eftilagimod alpha (“efti” or “IMP321”), a soluble LAG-3 fusion protein (LAG-3Ig), which is a first-in-class antigen presenting cell (APC) activator being explored in cancer in multiple clinical trials. The Company is also developing an agonist of LAG-3 (IMP761) for autoimmune disease. Additional LAG-3 product candidates, including antibodies for immune response modulation, are licensed to and being developed by Immutep’s large pharmaceutical partners.
Further information can be found on the Company’s website www.immutep.com or by contacting:
Australian Investors/Media:
Catherine Strong, Citadel-MAGNUS
+61 (0)406 759 268; cstrong@citadelmagnus.com
U.S. Media:
Tim McCarthy, LifeSci Advisors
+1 (917) 679 9282; tim@lifesciadvisors.com
FAQ
What is the date and time of Immutep's CEO presentation at The JMP Securities Hematology and Oncology Summit?
Where can I watch the live webcast of Immutep's CEO presentation?
What is the focus of Immutep Limited's research?
What is Immutep's lead product candidate?
What are the main areas of development for Immutep Limited?
